Sign inJoin waitlistJoin the waitlist

Coral Omene

Program Director, Breast Cancer Disparities Research · Rutgers Health

Credentials: · · · · ·

History

Breast Cancer Disparities Research · Rutgers Health
Present
Rutgers Health
Present
Rutgers Health
Present

NYU Grossman School of Medicine
2006–2008
Internal Medicine
New York Presbyterian Hospital
2003–2006
Columbia University College of Physicians and Surgeons
Columbia Univ Coll of Phys & Surgeons
1999–2003

Research

Caffeic acid phenethyl ester (CAPE), derived from a honeybee product propolis, exhibits a diversity of anti-tumor effects in pre-clinical models of human breast cancer
Cancer Letters · 2011 · 146 citations
Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer
Review · Frontiers in Oncology · 2021 · 129 citations
CD20-induced B cell death can bypass mitochondria and caspase activation
Leukemia · 2002 · 73 citations

Shridar Ganesan
8 papers
Mridula George
6 papers
Deborah Toppmeyer
5 papers
Song Yao
4 papers
Nisha Ohri
3 papers
SL
Seth Lederman
3 papers
Thaer Khoury
3 papers
Alexandra Thomas
2 papers
Amy Clark
2 papers
AS
Amy Sanford
2 papers
Angela DeMichele
2 papers
Anne Wallace
2 papers

Grants

Modifying The Risk For Developing Triple Negative Breast Cancer (TNBC)
National Cancer Institute · K08
Contact PI · $1M · Rbhs -Cancer Institute of New Jersey
2012–2021
Marc Predoctoral Fellowship
National Institute of General Medical Sciences · F31
Contact PI · $171.1K · Columbia Univ New York Morningside
1995

Clinical trials

Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer
Principal investigator · Recruiting
Rutgers, The State University of New Jersey
2024–2028
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
Principal investigator · Recruiting · Phase 2
Rutgers, The State University of New Jersey
2024–2027
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Site PI · Recruiting · Phase 3
Stemline Therapeutics, Inc.
2024–2032
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
Site PI · Recruiting · Phase 2
Oana Danciu
2022–2029